Navigation Links
BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease

WAKEFIELD, Mass.--(BUSINESS WIRE)--Jul 10, 2007 - BusinessWeek published an article on July 6 discussing the race by pharmaceutical and biotechnology companies to be first to bring to market an effective angiogenesis treatment for cardiovascular disease. While angiogenesis therapies are being pursued by Sanofi-Aventis, Boston Scientific, Baxter, and Genzyme, among others, the article highlights a very promising new biological therapy for advanced coronary artery disease (CAD) patients, FGF-1, from CardioVascular BioTherapeutics Inc. (CVBT).

BusinessWeek cites The Bruckner Group's (BGI) study presenting the preliminary value proposition for FGF-1 use in advanced coronary artery disease patients. According to BGI's study, FGF-1 has the potential to reduce treatment costs of advanced CAD patients by 20% over a five-year period after treatment.

Here is a link to the article: www.businessweek.com/technology/content/jul2007/tc2007075_259598.htm

"It's exciting when a breakthrough treatment appears with the potential to transform how we treat patients with a serious and costly disease like coronary artery disease," said Michael Russo, Partner, The Bruckner Group. "Typically, breakthrough treatments add cost to the healthcare system. BGI's study indicates, however, that FGF-1 could actually reduce total treatment costs, by as much as 20% over five years. We are looking forward to gathering evidence from the ongoing clinical trials to conclusively prove these points," Russo said.

According to Daniel Montano, CEO of CardioVascular BioTherapeutics, "The Bruckner Group's ongoing development of FGF-1's value proposition has been critical to FGF-1's commercial development. BGI's findings are allowing CVBT to have meaningful discussions with payers and employers. We are telling them that not only is a clinical breakthrough on the horizon that has the potential to revolutionize treatment for coronary artery disease patients, but more importantly, it will produce great savings. Given the growing financial strains on the U.S. healthcare system, our message is being met with great enthusiasm by payers, employers, and other stakeholders," Montano said.

About The Bruckner Group (BGI):

The Bruckner Group provides strategic advice to pharmaceutical and biotechnology executives. BGI is the leading expert in healthcare value strategy, helping pharmaceutical and biotechnology companies enhance and maximize the healthcare value of new therapies in development, prove that value at launch to payers and other stakeholders, and leverage that value post-launch to dominate markets.

Contact

The Bruckner Group
David Balekdjian, Partner, 781-245-4454


'"/>




Related medicine technology :

1. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
2. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
3. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
4. Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma
5. Expert Opinion Highlights Avigens AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
8. July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia
9. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
10. Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex (ancrod)
11. Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2018)... ... 14, 2018 , ... EnviroLeather™ by LDI, a leader in ... SmithGroup, the Carto.graph collection is a graphic expression of mapping the San Francisco ... healthcare interior designer, Aileen Avila-Banaag to design the Carto.graph Collection. “I was working ...
(Date:9/13/2018)... ASTORIA, N.Y. (PRWEB) , ... September 13, 2018 , ... ... now open. Located at 31-57 31st St., the new arrival is called Form50 ... machine created by Sebastien Lagree called The Megaformer™ - a hybrid Pilates reformer with ...
(Date:9/13/2018)... ... September 13, 2018 , ... ... on developing and commercializing gastrointestinal therapeutics, has secured acceptance of Camligo™ as ... and Drug Administration (FDA) and European Medicines Agency (EMA), have accepted Camligo™ ...
Breaking Medicine Technology:
(Date:9/22/2018)... ... September 21, 2018 , ... Liz Dudek, Director of ... Sept. 25 Hillsborough County Chapter meeting of the Florida Assisted Living Association (FALA) at ... , Dudek’s presentation will provide an overview of the success of the first ...
(Date:9/22/2018)... Calif. (PRWEB) , ... September 22, 2018 , ... ... and sizes. In fact, there are actually 29 different categories listed in section ... include charitable or religious organizations (often referred to as a 501(c)(3)), private foundations, ...
(Date:9/15/2018)... ... September 14, 2018 , ... Last night, Congressional leadership released ... for Labor, Health and Human Services and Education (LHHS) and Defense. Specifically, the ... Program, and $286.5 million for the Title X Family Planning Program for FY ...
(Date:9/12/2018)... ... ... De Novo Strategies for Getting Your Medical Device Approved:, What is the ... 3:00 p.m. ET, http://www.fdanews.com/denovostrategies , What’s the best route for obtaining ... are the best practices to win approval? , These are some of the questions ...
(Date:9/12/2018)... ... ... Glori Blends will be attending the CBD Expo West 2018 in an ... presentations, panel discussions and a special pavilion for pet line products. The creators of ... assist customers with the best selection for their individual needs. , The address of ...
Breaking Medicine News(10 mins):